Agios to Present at the Canaccord Genuity 37th Annual Growth Conference Thursday, August 10, 2017
CAMBRIDGE, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Canaccord Genuity 37th Annual Growth Conference in Boston on Thursday, August 10, 2017 at 9:30 a.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Kendra Adams, 617-844-6407
Senior Director, Investor & Public Relations
Renee Leck, 617-649-8299
Senior Manager, Investor & Public Relations